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ABSTRACT

Objective: The objective of this selective EBM review is to determine whether or not hylan
injections are more effective in reducing stiffness in primary knee osteoarthritis compared to
hyaluronic acid derivative injections.
Study Design: Review of three published, English language randomized controlled trials
published in 2007, 2008 and 2011.
Date Sources: Three randomized control trials were found using PubMed. These studies
compared the efficacy and safety of hylan injections and hyaluronic acid derivative injections for
reducing stiffness in primary knee osteoarthritis.
Outcome(s) Measured: The efficacy and tolerability of hylan injections for the treatment of
stiffness in patients with knee osteoarthritis. The clinical outcome was measured using the
Western Ontario McMaster University Osteoarthritis Index (WOMAC). The incidence of
serious adverse events including septic arthritis, anaphylactic shock, pain, effusion, erythema and
injection site hematoma. Adverse events were patient reported with investigator documentation.
Results: Juni (2007)8 found that patients given hylan injections compared to hyaluronic acid
derivative injections showed equal efficacy in improving clinical performance in reducing the
WOMAC subscores including the stiffness subscore. Raman (2008)9 found improvement in the
WOMAC stiffness subscale for both hylan and hyaluronic acid derivative injections, but no
statistical difference observed between the two injections. Pavelka (2011)10 found both
preparations equally effective in reducing the WOMAC stiffness subscale with no significant
difference between the hylan and hyaluronic acid derivative injection treatment groups.
Conclusions: Results from the three randomized controlled studies demonstrate that both hylan
and hyaluronic acid derivative injections show equal efficacy in reducing stiffness in primary
knee osteoarthritis.
Keywords: Knee osteoarthritis, hylan, hyaluronic acid.
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INTRODUCTION
Osteoarthritis is a progressive degenerative joint disease that affects joint cartilage and
bone leading to joint pain and stiffness. Osteoarthritis is the most common form of arthritis and
frequently occurs in the hand joints, spine, hips, knees and great toes.1 The diagnosis of
osteoarthritis is becoming more prevalent as more people are living longer and the population
obesity rates continue to increase. As there is no proven treatment to reverse osteoarthritis, the
goal has become to relieve symptoms and improve function as conservatively as possible.1
Osteoarthritis is one of the most prominent causes of disability in the United States.1
Knee osteoarthritis is typically managed by primary care practioners including physician
assistants in combination with orthopedic surgeons. In 2010, osteoarthritis accounted for 21.7
million of all arthritis-related ambulatory medical visits.2 Patients diagnosed with osteoarthritis
have a higher risk of death compared to the general population.3 Osteoarthritis of the knee affects
approximately 13% of women and 10% of men aged 60 years and older.3 Knee and hip joint
replacements accounts for 35% of total arthritis-related procedures during hospitalization.2
According to the CDC, the rate of total knee replacements have increased 217% from 1992 to
2011.2 Total knee replacement estimated costs due to hospital expenditures totaled
approximately 28.5 billion in 2009.2
While the underlying etiology of knee osteoarthritis is unknown, research has shown that
osteoarthritis results from local inflammation, genetics, cellular and biochemical processes.4 Risk
factors for osteoarthritis include advanced age, obesity, occupation, previous injury and a
positive family history.4 Osteoarthritis of the knee is a progressive chronic disease with clinical
manifestations including joint pain, swelling, instability and stiffness. Osteoarthritic pain is
described as a constant dull and aching pain that increases with impact and relieved by rest.4
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Patients describe their pain as being worse as the day progresses. Limited range of motion and
stiffness may be due to osteophyte formation in the knee and capsular thickening. Osteoarthritis
of the knee is diagnosed clinically but can be confirmed with radiographic imaging displaying
joint space narrowing, osteophytes, and subchondral sclerosis.4
The goal of treatment for patients with knee osteoarthritis is to reduce pain and improve
function which can be achieved with nonpharmacological treatment, pharmacologic treatment or
surgically. Typical nonpharmacologic treatment include physical therapy, aquatic therapy,
physical activity, weight management, and the use of assisted devices.1 Initial pharmacologic
treatment includes acetaminophen, COX-2 inhibitors, nonsteroidal anti-inflammatories, capsaicin
cream, and diclofenac gels.1 Intraarticular joint injections of glucocorticoid as well as
viscosupplementation injections such as hylan and hyaluronic acid are recommended after failing
primary treatment options. Hylan and hyaluronic acid injections have been proposed for
treatment of osteoarthritis based on the restoration of lubrication from the injection.5 Total joint
replacement, the most invasive treatment option is reserved for severe knee osteoarthritis.
Hyaluronic acid naturally occurs in the synovial fluid around the knee joint and absorbs shock.5
Patients with osteoarthritis have a decreased amount of hyaluronic acid found in their joints.5
Viscosupplementation augments hyaluronic acid to the joint in efforts to increase lubrication and
decrease joint pain and stiffness. This paper evaluates three randomized controlled studies
comparing the safety and efficacy of hylan and hyaluronic acid derivative injections for reducing
stiffness in patients with primary knee osteoarthritis.
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OBJECTIVE
The objective of this selective EBM review is to determine whether or not hylan
injections are more effective in reducing stiffness in primary knee osteoarthritis compared to
hyaluronic acid derivative injections.
METHODS
This review consists of three randomized controlled trials which were selected based on
relevance and patient oriented evidence that matters (POEMS). Although each of the trials had
specific criteria, the mutual criteria for the studies included men and non-pregnant females with
radiologically confirmed knee osteoarthritis aged 18 or older. All studies included intra-articular
hylan injections once weekly for three consecutive weeks as the intervention therapy. The
intervention therapy was compared to intra-articular hyaluronic acid injections. The outcomes
measured were the efficacy and tolerability of hylan injections for the treatment of stiffness in
patients with knee osteoarthritis. The incidence of serious adverse events included septic
arthritis, anaphylactic shock, pain, effusion, erythema and injection site hematoma.
Key words include knee osteoarthritis, hylan, hyaluronic acid were used to generate the
articles. Once these articles were generated, only randomized control trials published after 2006
were used and selected based on the relevance and the importance of outcome to the patient. The
articles chosen were published in English and published in peer-reviewed journals. The
performed searches included the use of PubMed database. Inclusion criteria included
randomized controlled trial prospective studies and included patients who were 18 years and
older with primary knee osteoarthritis. Exclusion criteria included patients who received
previous intra-articular treatment with corticosteroids, local anesthetic agents or
viscosupplementation agents in the past 3 months to the study. Statistics used in this review and
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calculated by the author using dichotomous data included relative risk increase (RRI), absolute
risk increase (ARI), numbers needed to harm (NNH) and p-values. Table 1 displays the
characteristics of the included studies.
Table 1: Demographics & Characteristics of included studies
Study

Juni8
(2007)

Type

Patient
blind

# Pts

660

RCT

Raman9
(2008)

Double
blind
RCT

Age

63.3
±
12.3

392

42-82

Inclusion

Exclusion

W/D

Interventions

Criteria

Criteria

Men and nonpregnant women
with
radiographically
confirmed knee
osteoarthritis with
symptoms for at
least 6 months and
reported pain on
most days for the
previous 3 months;
Did not respond to
acetaminophen or
nonsteroidal antiinflammatory drugs

Inflammatory joint disease;
Previous
viscosupplementation
treatment within 6 months;
Previous replacement
surgery in the affected
knee; Chondrocalcinosis
with evidence from
radiographs or synovial
fluid analysis; Infection in
or around affected knee or
relevant skin disease
surrounding injection site

8

A high
molecular
weight crosslinked hylan
derived from
rooster combs
(Synvisc;
Genzyme,
Cambridge, MA)

Minimum pain score
of 6 on a visual
analogue scale (010, 10 as worst pain)
in the study knee;
Patients with
primary
osteoarthritis of the
study knee affecting
the tibio-femoral +/the patello-femoral
compartment

Previous surgery to study
knee; Previous intraarticular treatment with
corticosteroids, local
anesthetic agents or
viscosupplementation
agents to the study knee;

32

Bilateral knee osteoarthritis
which warranted treatment

Administered as
a series of 3
weekly
injections

Hylan G-F 20
with average
molecular
weight of 6
million Daltons
administered as
a series of 3
weekly
injections
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Pavelka10 Double
blind
RCT

381

40-81

Radiologically
confirmed diagnosis
of osteoarthritis of
the affected and
clinically diagnosed
by an American
Colleague of
Rheumatology

Body Mass Index ≥32
kg/m^2;
Viscosupplementation to
knee within the past year or
initiation of physical
therapy in the past 3
months;

27

Once weekly for
3 weeks
16mg/2ml
(0.8%) of intraarticular hylan A

OUTCOMES MEASURED
All studies measured the efficacy outcome of improvement of stiffness using the Western
Ontario McMaster University Index (WOMAC) stiffness subscale. In the study by Juni (2007)8,
the WOMAC stiffness subscale was measured at baseline and 6 months post injection. In the
study by Raman (2008)9, the WOMAC stiffness subscale was measured at 3, 6 and 12 months
following treatment. In the study by Pavelka (2011)10, the WOMAC stiffness subscale was
measured at baseline and 26 weeks post treatment. The safety outcome was measured by selfreported adverse events at each follow up visit with investigator documentation of adverse events
including septic arthritis, anaphylactic shock, pain, effusion, erythema and injection site
hematoma. Safety outcomes were also assessed using patient-administered questionnaires.
RESULTS
This review assesses three randomized controlled trials to evaluate the efficacy of intraarticular hylan injections in reducing stiffness in primary knee osteoarthritis compared to
hyaluronic acid derivative intra-articular injections. In the study by Juni8, 660 patients with
symptomatic knee osteoarthritis were enrolled in the study. Patients were randomly dived into
three groups by a computer-generated program: first group of 222 patients were treated using
intra-articular hylan injections; the second group of 219 patients were treated using intra-articular
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avian hyaluronic acid injections and the third group of 219 patients were treated using intraarticular bacterial hyaluronic acid injections (third group will not be discussed in this review).
The patients in each group received one cycle of three intra-articular injections of 2ml per knee
treated at weekly intervals. All injections were performed per the Swiss Association of
Rheumatologists guidelines.

Data were collected at baseline and 6 months after the last intra-

articular injection was performed. At baseline, all three groups had similar clinical
characteristics with no statistical differences regarding the WOMAC stiffness subscale.
WOMAC scores were analyzed using analysis of covariance adjusted for baseline values. The
results determined that there was a 0.1 (95% CI -0.3, 0.4) change for the WOMAC stiffness
score from baseline between the hylan and hyaluronic acid derivative injections.
Local adverse events including effusion and flare were obtained during the first 6 months
of the study. During the first 6 months of the study, 9.5% of patients receiving the hylan
injection experienced local adverse events and 7.3% of patients receiving the hyaluronic acid
injection experienced local adverse events with a difference of 2.2% (95% Cl 2.4, 6.7). The
trend toward an increase in local adverse events in the hylan receiving group increased in the
second cycle resulting in a difference of 6.4% (95% Cl 0.6, 12.2). During the first 6 months of
the study, 15 of 222 patients receiving hylan and 25 of 438 patients receiving hyaluronic acid
experienced serious adverse events. Serious adverse events are characterized as neoplasms,
endocrine and metabolic disorders, mental and behavior disorders, disorders of the nervous
system, disorders of the circulatory system, disorders of connective tissues, disorder of
genitourinary system, septic arthritis and anaphylactic shock (which only occurred after injection
of hylan). To measure safety of hylan and hyaluronic acid derivative, the NNH was calculated
and resulted as -76.
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Table 3: Safety and adverse events (calculated data for treatment using dichotomous data)
CER
(Proportion
of patients
having
adverse
events with
hylan)

6.8%

EER
(Proportion
of patients
having
adverse
events with
hyaluronic
acid
derivative)
5.5%

Relative risk
increase
(RRI)

Absolute
risk
increase
(ARI)

Numbers
needed to
harm (NNH)

95% CI

-19.1%

-1.3%

-76

-2.4, 6.7

In the prospective randomized study completed by Raman9, 392 patients who met criteria
of having primary knee osteoarthritis participated in this study. There were no substantial
differences in the age or sex between the two groups. There were 199 patients who received
hylan intra-articular injections and 193 patients received hyaluronic acid intra-articular
injections. All patients were randomly allocated to receive either hylan or hyaluronic acid
injections by computer generator. Hylan was administered in a series of 3 weekly injections and
hyaluronic acid was administered in a series of 5 weekly injections per the manufacturer’s
recommendations. All injections were performed by the same surgeon using a default blind
technique. Patients were informed to be 24 hours analgesia free before baseline measurement
and were told to avoid non-steroidal anti-inflammatories for 6 months. Data were collected
using the WOMAC stiffness subscale at 3 months, 6 months and 12 months post treatment.
There was improvement in the WOMAC stiffness subscale at 3,6 and 12 months post treatment
and no statistical difference observed between the two groups at any follow up visit.
Figure 1: WOMAC improvement at 6 months
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Figure 1: Raman R, Dutta A, Day N, Sharma HK, Shaw CJ, Johnson GV. Efficacy of hylan G-F
20 and sodium hyaluronate in the treatment of osteoarthritis of the knee -- a prospective
randomized clinical trial.
Safety and adverse events were evaluated at each patient visit throughout the study.
There were 39 patients who reported treatment related adverse events in the hylan injection
group while 30 patients reported adverse events in the hyaluronate group. There was 1 severe
adverse event reported within the hylan group in which the patient was admitted to the hospital
and diagnosed with “pseudo-sepsis” in the knee. All other reports were characterized as minor
adverse events which mostly included injection site pain. 32 of the patient reported adverse
events in the hylan group occurred within 48 hours of the injection. Of note, there were no
systemic adverse events reported in either the hylan or hyaluronic acid injection groups. To
measure safety of hylan and hyaluronic acid derivative, the NNH was calculated and resulted as 25.
Table 5: Safety and adverse events (calculated data for treatment using dichotomous data)
CER

EER

Relative risk
increase
(RRI)

Absolute risk
increase
(ARI)

Numbers needed
to harm (NNH)

20%

16%

-20%

-4%

-25

In the double-blind randomized controlled trial by Pavelka10, 381 patients who were
diagnosed with primary knee osteoarthritis and aged between 40 and 81 years. 189 patients
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received hylan 16 mg/2 ml intra-articular injections while 192 patients received hyaluronic acid
derivative 16 mg/2ml intra-articular injections. Patients were randomized to receive once
weekly injections in a three-week interval for both groups. Patients were given a one month
supply of rescue medication however patients were informed to not consume this within 24 hours
prior to study visits. Use of rescue medications and adverse events were recorded in a patient
journal. The WOMAC stiffness subscale was measured at baseline and 26 weeks post treatment.
At baseline, there were no statistical differences between the groups. The results determined that
the WOMAC stiffness score from baseline to 26 weeks did not differ significantly between
treatment groups.
Table 6: WOMAC stiffness score at baseline and 26 month follow up
Baseline

WOMAC stiffness score

26 month follow up

Hylan

Hyaluronic Acid

Hylan

Hyaluronic Acid

50.1 ± 19.1

50.1 ± 19.4

25.8

25.7

Adverse reactions were assessed and reported throughout the 26 weeks. Adverse
reactions were characterized as injection site hematoma, injection site pain, arthralgia and joint
swelling. 5 adverse events were reported within the hylan injection group and 1 adverse event
was reported within the hyaluronic acid injection group. There was a total of 7 severe adverse
events reported: 6 events reported in the hylan injection group and 1 event reported in the
hyaluronic acid group. To measure safety of hylan and hyaluronic acid derivative, the NNH was
calculated and resulted as -41.
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Table 7: Safety and adverse events (calculated data for treatment using dichotomous data)
CER

EER

2.9%

0.54%

Relative risk
increase
(RRI)

Absolute risk
increase
(ARI)

Numbers needed
to harm (NNH)

-82.8%

-2.4%

-41

DISCUSSION
This systematic review of three randomized controlled trials evaluated the efficacy of
hylan compared to hyaluronic acid derivatives regarding improving stiffness in patients with
knee osteoarthritis. Unfortunately, there is not a cure for osteoarthritis or the process of a
degenerating joint. While viscosupplementation will not cure osteoarthritis, it has been used as a
therapeutic modality of knee osteoarthritis for several years. Viscosupplements including hylan
and hyaluronic acid derivative injections have been approved by the FDA for the treatment of
primary knee osteoarthritis. Viscosupplements are available in the United States however the
wholesale price is approximately $1,500 per knee for a treatment series.6 Most insurance
companies require failing conservative treatment options such as analgesics, physical therapy
and possibly receiving an intra-articular glucocorticoid injection before approving
viscosupplementation treatments.
There were notable limitations within the three randomized control trial studies. The first
limitation included the lack of a placebo control in all three trials. While all three trials used the
same hylan injection (Synvisc), there were three different hyaluronic acid derivative injections
used. In the study by Juni8, a non-cross linked medium molecular weight hyaluronic acid
derivative known as Orthovisc was used. In the study by Raman9, Hyalgan was used as the
hyaluronate viscous solution. A chemically non-modified sodium hyaluronate known as
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Sinovial was used in the study by Pavelka10. Secondly, the studies by Juni8 and Pavelka10
involved different physicians performing the viscosupplementation injections which can be
considered a limitation due to the variety of injection techniques. Viscosupplementation
injections require a precise technique to work effectively and limit adverse side effects.7
In the study by Raman9, the hyaluronic acid derivative injection required 5 injections
compared to the 3 injections required with the hylan creating a treatment bias. However, the
manufacturer of the hyaluronic acid injection recommended to follow their guidelines. Finally,
stiffness was assessed during the 6 month and 12 month follow up visits in the studies by Juni8
and Raman9. Extending the follow up time would allow for a better understanding of efficacy
and the hylan injection’s full effects in regards to improving stiffness.
CONCLUSION
Based on this systemic review of the three randomized controlled studies, hylan
injections do not prove to be more effective in reducing stiffness in primary knee osteoarthritis
compared to hyaluronic acid derivative injections. The WOMAC stiffness score used in all three
studies was assessed via questionnaire format. Future studies may benefit from an objective
form of measuring stiffness such as range of motion measurements performed at follow up visits.
The actual effectiveness of hylan or hyaluronic acid derivatives reducing stiffness in primary
knee osteoarthritis could not be proved in any three trials due to the lack of a placebo control
group. Although both viscosupplements were statistically equivalent in reducing stiffness, data
from all three studies displayed an increase number in local and severe adverse events within the
hylan injection groups. Future studies are warranted to evaluate the length of the effects of the
viscosupplements and how often injections series are recommended for patients with primary
knee osteoarthritis.
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